Home

About Us

Advertisement

Contact Us

  • Facebook
  • X
  • Instagram
  • Pinterest
  • WhatsApp
  • RSS Feed
  • TikTok

Interesting For You 24

Your Trusted Voice Across the World.

    • Contacts
    • Privacy Policy
Search

Genetic testing firm 23andMe files for bankruptcy as CEO resigns

March 24, 2025
Genetic testing firm 23andMe files for bankruptcy as CEO resigns

Gene testing firm 23andMe said on Sunday it had filed for Chapter 11 bankruptcy protection in order to facilitate its sale, after years of struggling to find a sustainable business model.

In a statement announcing the bankruptcy, the firm said its CEO, Anne Wojcicki, had resigned effective immediately. She will remain on the company’s board of directors.

RELATED: With 23andMe in ‘financial distress’ California official issues alert to customers

“After a thorough evaluation of strategic alternatives, we have determined that a court-supervised sale process is the best path forward to maximize the value of the business,” Mark Jensen, chair and member of the Special Committee of the board of directors, said in the statement.

Related Articles

Business |


Musk is positioned to profit off billions in new government contracts

Business |


Segway recalls 220,000 of its scooters due to a fall hazard that has resulted in 20 injuries

Business |


Micron’s shares fall after memory chip pricing hits hargins

Business |


Nvidia has traders on high alert as momentum withers

Business |


Tesla’s retail fans buy the stock at a pace never seen before

Late last year, the company said it was cutting about 40% of its workforce – around 200 employees – and discontinuing further development of all its therapies as part of a restructuring program, according to Reuters.

In September, all seven of the company’s independent directors resigned en masse, citing their frustration with the CEO’s “strategic direction” and efforts to take 23andMe private.

The company, which went public in 2021, had never made a profit. The stock shot up following the listing, briefly valuing the company at $6 billion. Wojcicki, who owned 49% of the company, became a billionaire.

Its core product, an at-home DNA testing kit, offers “personalized genetic insights” that the company says can flag potential health risks such as one’s likelihood of developing Alzheimers or certain cancers.

23andMe tried to convert one-time buyers into subscribers with the promise of continued feedback and personalized wellness plans but had reportedly fallen short of its goals.

This story has been updated with additional reporting and context.

The-CNN-Wire
& © 2025 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.

Featured Articles

  • Sale closed in San Jose: $2.3 million for a four-bedroom home

    Sale closed in San Jose: $2.3 million for a four-bedroom home

    June 10, 2025
  • Hundreds gather in San Jose, Oakland to protest ICE

    Hundreds gather in San Jose, Oakland to protest ICE

    June 10, 2025
  • Frederick Forsyth dies at 86; British author wrote acclaimed thrillers, including ‘Day of the Jackal’

    Frederick Forsyth dies at 86; British author wrote acclaimed thrillers, including ‘Day of the Jackal’

    June 10, 2025
  • Stanford assistant Eric Reveno named general manager of men’s basketball program

    Stanford assistant Eric Reveno named general manager of men’s basketball program

    June 10, 2025
  • Letters: Alameda County must implement Measure C

    Letters: Alameda County must implement Measure C

    June 9, 2025

Search

Latest Articles

  • Sale closed in San Jose: $2.3 million for a four-bedroom home

    Sale closed in San Jose: $2.3 million for a four-bedroom home

    June 10, 2025
  • Hundreds gather in San Jose, Oakland to protest ICE

    Hundreds gather in San Jose, Oakland to protest ICE

    June 10, 2025
  • Frederick Forsyth dies at 86; British author wrote acclaimed thrillers, including ‘Day of the Jackal’

    Frederick Forsyth dies at 86; British author wrote acclaimed thrillers, including ‘Day of the Jackal’

    June 10, 2025

181 Peachtree St NE, Atlanta, GA 30303 | +14046590400 | [email protected]

Scroll to Top